Larger effect size in composite kidney outcomes than in major cardiovascular events associated with sodium‐glucose cotransporter‐2 (SGLT2) inhibitors compared with glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs): A pooled analysis of type 2 diabetes trials

AIM: To compare treatment effect sizes between a composite kidney outcome (CKO) and three‐point major adverse cardiovascular event (MACE‐3) outcomes with use of sodium‐glucose cotransporter‐2 (SGLT2) inhibitors and glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs), and to investigate the relation...

Descripción completa

Detalles Bibliográficos
Autores principales: Diallo, Alhassane, Carlos‐Bolumbu, Miguel, Renard, Pr Eric, Galtier, Florence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087851/
https://www.ncbi.nlm.nih.gov/pubmed/36057779
http://dx.doi.org/10.1111/dom.14859

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087851/
https://www.ncbi.nlm.nih.gov/pubmed/36057779
http://dx.doi.org/10.1111/dom.14859

Ejemplares similares